Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
74°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Mirum Pharmaceuticals, Inc.
< Previous
1
2
3
4
5
6
Next >
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Today 18:00 EDT
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
Today 8:30 EDT
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
April 30, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
April 28, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
April 14, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
LIVMARLI Now Approved in Japan for ALGS and PFIC
March 27, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
February 26, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
February 24, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
February 19, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
January 13, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
November 14, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
November 04, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
October 31, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
October 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
July 31, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.